Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi, Michael Lim, Theodore L. DeWeese, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 13, pp. e498-e509
Closed Access | Times Cited: 772

Showing 1-25 of 772 citing articles:

Tertiary lymphoid structures in the era of cancer immunotherapy
Catherine Sautès‐Fridman, Florent Petitprez, Julien Caldéraro, et al.
Nature reviews. Cancer (2019) Vol. 19, Iss. 6, pp. 307-325
Open Access | Times Cited: 1303
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian, Aaron Lisberg, Krikor Bornazyan, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 7, pp. 895-903
Open Access | Times Cited: 980
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Joe‐Elie Salem, Ali Manouchehri, Melissa Moey, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 12, pp. 1579-1589
Open Access | Times Cited: 964
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
Yuanzeng Min, Kyle C. Roche, Shaomin Tian, et al.
Nature Nanotechnology (2017) Vol. 12, Iss. 9, pp. 877-882
Open Access | Times Cited: 616
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, et al.
Cancer Discovery (2017) Vol. 7, Iss. 7, pp. 675-693
Open Access | Times Cited: 581
Integrating oncolytic viruses in combination cancer immunotherapy
Praveen K. Bommareddy, Megha Shettigar, Howard L. Kaufman
Nature reviews. Immunology (2018) Vol. 18, Iss. 8, pp. 498-513
Closed Access | Times Cited: 562
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
Jason J. Luke, Jeffrey M. Lemons, Theodore Karrison, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 16, pp. 1611-1618
Open Access | Times Cited: 522
Current clinical trials testing the combination of immunotherapy with radiotherapy
Josephine Kang, Sandra Demaria, Silvia C. Formenti
Journal for ImmunoTherapy of Cancer (2016) Vol. 4, Iss. 1
Open Access | Times Cited: 354
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zengfu Zhang, Xu Liu, Dawei Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 351
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Wei Sang, Zhan Zhang, Yunlu Dai, et al.
Chemical Society Reviews (2019) Vol. 48, Iss. 14, pp. 3771-3810
Closed Access | Times Cited: 349
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Ugo Testa, Germana Castelli, Elvira Pelosi
Cancers (2018) Vol. 10, Iss. 8, pp. 248-248
Open Access | Times Cited: 324
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Linda Chen, Jacqueline Douglass, Lawrence Kleinberg, et al.
International Journal of Radiation Oncology*Biology*Physics (2017) Vol. 100, Iss. 4, pp. 916-925
Closed Access | Times Cited: 293
Organoid Models of Tumor Immunology
Kanako Yuki, Ning Cheng, Michitaka Nakano, et al.
Trends in Immunology (2020) Vol. 41, Iss. 8, pp. 652-664
Open Access | Times Cited: 289
PD-1/PD-L1 and immunotherapy for pancreatic cancer
Mengyu Feng, Guangbing Xiong, Zhe Cao, et al.
Cancer Letters (2017) Vol. 407, pp. 57-65
Closed Access | Times Cited: 284
Improving radiotherapy in cancer treatment: Promises and challenges
Helen H.W. Chen, Macus Tien Kuo
Oncotarget (2017) Vol. 8, Iss. 37, pp. 62742-62758
Open Access | Times Cited: 281
Self-Supplied Tumor Oxygenation through Separated Liposomal Delivery of H2O2 and Catalase for Enhanced Radio-Immunotherapy of Cancer
Xuejiao Song, Jun Xu, Chao Liang, et al.
Nano Letters (2018) Vol. 18, Iss. 10, pp. 6360-6368
Closed Access | Times Cited: 266
Safety of combining radiotherapy with immune-checkpoint inhibition
William L. Hwang, Luke Pike, Trevor J. Royce, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 8, pp. 477-494
Closed Access | Times Cited: 246
Selenium‐Containing Nanoparticles Combine the NK Cells Mediated Immunotherapy with Radiotherapy and Chemotherapy
Shiqian Gao, Tianyu Li, Ye Guo, et al.
Advanced Materials (2020) Vol. 32, Iss. 12
Closed Access | Times Cited: 244
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)
Chengqiang Li, Shengguang Zhao, Yuyan Zheng, et al.
European Journal of Cancer (2020) Vol. 144, pp. 232-241
Closed Access | Times Cited: 234
Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data
Eric J. Lehrer, Jennifer Peterson, Paul D. Brown, et al.
Radiotherapy and Oncology (2018) Vol. 130, pp. 104-112
Closed Access | Times Cited: 221
Engineering nanoparticles to locally activate T cells in the tumor microenvironment
Dangge Wang, Tingting Wang, Haijun Yu, et al.
Science Immunology (2019) Vol. 4, Iss. 37
Open Access | Times Cited: 218
Contemporary radiotherapy: present and future
Ravi A. Chandra, Florence K. Keane, Francine E.M. Voncken, et al.
The Lancet (2021) Vol. 398, Iss. 10295, pp. 171-184
Closed Access | Times Cited: 211
β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy
Mark J. Bucsek, Guanxi Qiao, Cameron R. MacDonald, et al.
Cancer Research (2017) Vol. 77, Iss. 20, pp. 5639-5651
Open Access | Times Cited: 204
Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery
Jack M. Qian, James B. Yu, Harriet M. Kluger, et al.
Cancer (2016) Vol. 122, Iss. 19, pp. 3051-3058
Open Access | Times Cited: 199
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
Yiyi Yan, Anagha Kumar, Heidi D. Finnes, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 195
Page 1 - Next Page

Scroll to top